Cargando…

Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells

Multiple myeloma (MM) still remains an incurable disease, at least because of the existence of cell-adhesion mediated drug-resistant MM cells and/or continuous recruitment of presumed MM cancer stem cell-like cells (CSCs). As a new alternative treatment modality, immunological approaches using monoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada, Takeshi, Ozaki, Shuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124849/
https://www.ncbi.nlm.nih.gov/pubmed/25143955
http://dx.doi.org/10.1155/2014/965384
_version_ 1782329685696315392
author Harada, Takeshi
Ozaki, Shuji
author_facet Harada, Takeshi
Ozaki, Shuji
author_sort Harada, Takeshi
collection PubMed
description Multiple myeloma (MM) still remains an incurable disease, at least because of the existence of cell-adhesion mediated drug-resistant MM cells and/or continuous recruitment of presumed MM cancer stem cell-like cells (CSCs). As a new alternative treatment modality, immunological approaches using monoclonal antibodies (mAbs) and/or cytotoxic T lymphocytes (CTLs) are now attracting much attention as a novel strategy attacking MM cells. We have identified that HM1.24 [also known as bone marrow stromal cell antigen 2 (BST2) or CD317] is overexpressed on not only mature MM cells but also MM CSCs. We then have developed a humanized mAb to HM1.24 and defucosylated version of the mAb to adapt to clinical practice. Moreover, we have successfully induced HM1.24-specific CTLs against MM cells. The combination of these innovative therapeutic modalities may likely exert an anti-MM activity by evading the drug resistance mechanism and eliminating presumed CSCs in MM.
format Online
Article
Text
id pubmed-4124849
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-41248492014-08-20 Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells Harada, Takeshi Ozaki, Shuji Biomed Res Int Review Article Multiple myeloma (MM) still remains an incurable disease, at least because of the existence of cell-adhesion mediated drug-resistant MM cells and/or continuous recruitment of presumed MM cancer stem cell-like cells (CSCs). As a new alternative treatment modality, immunological approaches using monoclonal antibodies (mAbs) and/or cytotoxic T lymphocytes (CTLs) are now attracting much attention as a novel strategy attacking MM cells. We have identified that HM1.24 [also known as bone marrow stromal cell antigen 2 (BST2) or CD317] is overexpressed on not only mature MM cells but also MM CSCs. We then have developed a humanized mAb to HM1.24 and defucosylated version of the mAb to adapt to clinical practice. Moreover, we have successfully induced HM1.24-specific CTLs against MM cells. The combination of these innovative therapeutic modalities may likely exert an anti-MM activity by evading the drug resistance mechanism and eliminating presumed CSCs in MM. Hindawi Publishing Corporation 2014 2014-07-17 /pmc/articles/PMC4124849/ /pubmed/25143955 http://dx.doi.org/10.1155/2014/965384 Text en Copyright © 2014 T. Harada and S. Ozaki. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Harada, Takeshi
Ozaki, Shuji
Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells
title Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells
title_full Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells
title_fullStr Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells
title_full_unstemmed Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells
title_short Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells
title_sort targeted therapy for hm1.24 (cd317) on multiple myeloma cells
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124849/
https://www.ncbi.nlm.nih.gov/pubmed/25143955
http://dx.doi.org/10.1155/2014/965384
work_keys_str_mv AT haradatakeshi targetedtherapyforhm124cd317onmultiplemyelomacells
AT ozakishuji targetedtherapyforhm124cd317onmultiplemyelomacells